相关临床试验
4
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
进行中（未招募）
3
75.0%
已完成
1
25.0%
暂无批准数据
- Precipio (PRPO) combines clinical laboratory services with proprietary diagnostic product development, with pathology services focused primarily on hematologic cancers. - Biodesix (BDSX) provides blood-based diagnostic testing for lung disease, including tests that assess cancer risk in lung nodules and guide post-diagnosis treatment. - Biodesix has outperformed Precipio over the past three months (up 64.5% vs. 26.4%) and over the past year (up 150.9% vs. 112%). - Both stocks trade below the Zacks Medical sector average EV/S of 2.92X, with PRPO at 1.90X and BDSX at 2.89X.
- Precision medicine company Oncimmune Holdings has entered administration after failing to secure a buyer for its German subsidiary or raise additional capital to meet short-term funding needs. - The University of Nottingham spin-out has requested suspension of its shares on the AIM market, with trading halted as of March 17, 2025, following a 93% stock value decline over the past year. - Alvarez & Marsal Europe LLP managing directors will be appointed as administrators to preserve remaining business value for creditors, marking a significant setback for the autoantibody profiling services provider.
